Literature DB >> 10473523

Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individuals.

M Suzuki1, C S Dezzutti, A Okayama, N Tachibana, H Tsubouchi, N Mueller, R B Lal.   

Abstract

To determine the mechanism of the purified protein derivative (PPD)-specific hyporesponsiveness in Mycobacterium bovis BCG-vaccinated human T-cell leukemia virus type 1 (HTLV-1)-infected individuals, we examined cytokine production in response to PPD in the following four groups of individuals: (i) HTLV-negative, PPD nonresponders (n = 11; NN); (ii) HTLV-negative, PPD responders (n = 18; NP); (iii) HTLV-positive, PPD nonresponders (n = 15; PN); and (iv) HTLV-positive, PPD responders (n = 15; PP). In vitro stimulation with PPD resulted in both proliferative responses and gamma interferon (IFN-gamma) production in NP and PP (P < 0.02), with minimal proliferation and IFN-gamma production in the NN and PN groups. Further, PPD-specific interleukin 10 (IL-10) production was significantly reduced in the PN group (P < 0.01), while the other groups had comparable levels. Cytokine reconstitution experiments demonstrated that while addition of recombinant IL-12 (rIL-12) plus anti-IL-4 restored PPD-specific responses in the NN group, it had no effect in the PN group. However, addition of rIL-12 resulted in the increased production of IFN-gamma in both nonresponder groups (NN and PN), suggesting that the lack of IFN-gamma production was not responsible for the PPD anergy. We conclude that PPD-specific anergy in HTLV-1-infected individuals appears to be due in part to their inability to respond to rIL-12.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473523      PMCID: PMC95760          DOI: 10.1128/CDLI.6.5.713-717.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  16 in total

1.  Human T cell leukemia/lymphoma virus type I infection of a CD4+ proliferative/cytotoxic T cell clone progresses in at least two distinct phases based on changes in function and phenotype of the infected cells.

Authors:  H Yssel; R de Waal Malefyt; M D Duc Dodon; D Blanchard; L Gazzolo; J E de Vries; H Spits
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

2.  Suppression of tuberculin skin reaction in healthy HTLV-I carriers from Japan.

Authors:  N Tachibana; A Okayama; J Ishizaki; T Yokota; E Shishime; K Murai; S Shioiri; K Tsuda; M Essex; N Mueller
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

3.  Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers.

Authors:  K Murai; N Tachibana; S Shioiri; E Shishime; A Okayama; J Ishizaki; K Tsuda; N Mueller
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

Review 4.  Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection.

Authors:  P Höllsberg; D A Hafler
Journal:  N Engl J Med       Date:  1993-04-22       Impact factor: 91.245

5.  Decreased reactivity to PPD among HTLV-I carriers in relation to virus and hematologic status.

Authors:  S L Welles; N Tachibana; A Okayama; S Shioiri; S Ishihara; K Murai; N E Mueller
Journal:  Int J Cancer       Date:  1994-02-01       Impact factor: 7.396

6.  Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I.

Authors:  R Yarchoan; H G Guo; M Reitz; A Maluish; H Mitsuya; S Broder
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

7.  Human interleukin-10 can directly inhibit T-cell growth.

Authors:  K Taga; H Mostowski; G Tosato
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

8.  Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells.

Authors:  T Germann; M K Gately; D S Schoenhaut; M Lohoff; F Mattner; S Fischer; S C Jin; E Schmitt; E Rüde
Journal:  Eur J Immunol       Date:  1993-08       Impact factor: 5.532

9.  Cytokine induction in HTLV-I associated myelopathy and adult T-cell leukemia: alternate molecular mechanisms underlying retroviral pathogenesis.

Authors:  C L Tendler; S J Greenberg; J D Burton; D Danielpour; S J Kim; W A Blattner; A Manns; T A Waldmann
Journal:  J Cell Biochem       Date:  1991-08       Impact factor: 4.429

10.  Infection of human T lymphotropic virus-I-specific immune T cell clones by human T lymphotropic virus-I.

Authors:  H Mitsuya; R F Jarrett; J Cossman; O J Cohen; C S Kao; H G Guo; M S Reitz; S Broder
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

View more
  6 in total

1.  Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens.

Authors:  Rita Elizabeth Mascarenhas; Cláudia Brodskyn; Geisa Barbosa; Jorge Clarêncio; Antônio Souza Andrade-Filho; Frederico Figueiroa; Bernardo Galvão-Castro; Fernanda Grassi
Journal:  Clin Vaccine Immunol       Date:  2006-05

2.  HTLV-1 infection is associated with a history of active tuberculosis among family members of HTLV-1-infected patients in Peru.

Authors:  K Verdonck; E González; W Schrooten; G Vanham; E Gotuzzo
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

3.  Impairment of the humoral and CD4(+) T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid.

Authors:  Anselmo Souza; Silvane Santos; Lucas P Carvalho; Maria Fernanda R Grassi; Edgar M Carvalho
Journal:  Hum Immunol       Date:  2016-06-06       Impact factor: 2.850

4.  Prevalence of human T-cell lymphotropic virus type 1 infection in hospitalized patients with tuberculosis.

Authors:  M de Lourdes Bastos; B Osterbauer; D L Mesquita; C A Carrera; M J Albuquerque; L Silva; D N Pereira; L Riley; E M Carvalho
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373

5.  Integrated miRNA and mRNA expression profiling to identify mRNA targets of dysregulated miRNAs in pulmonary tuberculosis.

Authors:  Xing Zhang; Min Zhu; Xiaolong Hu
Journal:  Epigenomics       Date:  2018-07-27       Impact factor: 4.778

6.  Influence of HTLV-1 on the clinical, microbiologic and immunologic presentation of tuberculosis.

Authors:  Maria de Lourdes Bastos; Silvane B Santos; Anselmo Souza; Brooke Finkmoore; Ohana Bispo; Tasso Barreto; Ingrid Cardoso; Iana Bispo; Flávia Bastos; Daniele Pereira; Lee Riley; Edgar M Carvalho
Journal:  BMC Infect Dis       Date:  2012-08-28       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.